Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer

Keyphrases

• Childhood Cancer 100%
• Anthracyclines 100%
• Cardiotoxicity 100%
• Medical Intervention 100%
• Enalapril 100%
• Anthracycline-induced Cardiotoxicity 85%
• Randomized Controlled Trial 71%
• Childhood Cancer Patients 57%
• Placebo 57%
• Phosphocreatine 57%
• Heart Failure 42%
• High Risk 42%
• Cardiac Dysfunction 42%
• Cardiac Function 42%
• Review Authors 42%
• Echocardiographic 28%
• Clinical Outcomes 28%
• Overall Survival 28%
• Control Method 28%
• Dizziness 28%
• Hypotension 28%
• Left Ventricular Function 28%
• Wall Stress 28%
• Controlled Clinical Trial 28%
• End-systolic 28%
• Pediatric Oncology 14%
• Adverse Events 14%
• International Society 14%
• Selection Criteria 14%
• Treatment Complications 14%
• Cochrane Library 14%
• Embase 14%
• Leukemia Patients 14%
• Quality of Life 14%
• Vitamin E 14%
• No Significant Difference 14%
• MEDLINE 14%
• Data Extraction 14%
• Risk of Bias 14%
• Preadolescent children 14%
• Vitamin C 14%
• Fisher's Exact Test 14%
• First Year 14%
• National Institutes of Health 14%
• Risk of Bias Assessment 14%
• Ongoing Trials 14%
• Ovid 14%
• World Health Organization 14%
• Conference Proceedings 14%
• Risk Ratio 14%
• Cochrane Central Register of Controlled Trials 14%
• Functional Outcome 14%
• International Conference 14%
• Late Complications 14%
• Methodological Limitations 14%
• Long-term Complications 14%
• American Society of Clinical Oncology 14%
• American Society of Hematology 14%
• Search Methods 14%
• Cochrane Review 14%
• Coenzyme Q10 14%
• One-parameter 14%
• Adenosine Triphosphate 14%
• 95% Confidence Interval 14%
• Statistically Significant Difference 14%
• Cochrane Handbook 14%
• Health Registers 14%
• Failure Development 14%

Medicine and Dentistry

• Childhood Cancer 100%
• Anthracycline 100%
• Cardiotoxicity 100%
• Medical Intervention 100%
• Enalapril 63%
• Randomized Controlled Trial 45%
• Placebo 36%
• Creatine Phosphate 36%
• Heart Function 27%
• Congestive Heart Failure 27%
• Overall Survival 18%
• Controlled Clinical Trial 18%
• Dizziness 18%
• Hypotension 18%
• Malignant Neoplasm 9%
• Complication of Treatment 9%
• Systematic Review 9%
• Quality of Life 9%
• Adenosine Triphosphate 9%
• Alpha Tocopherol 9%
• Clinician 9%
• Fisher Exact Test 9%
• Hematology 9%
• Patient with Leukemia 9%
• Post-Hoc Analysis 9%
• Clinical Oncology 9%
• Coenzyme Q10 9%
• Adolescence 9%
• Oral 9%
• Side Effect 9%
• Ascorbic Acid 9%
• Adverse Event 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Anthracycline 100%
• Childhood Cancer 100%
• Cardiotoxicity 100%
• Enalapril 63%
• Randomized Controlled Trial 45%
• Placebo 36%
• Creatine Phosphate 36%
• Congestive Heart Failure 27%
• Overall Survival 18%
• Controlled Clinical Trial 18%
• Hypotension 18%
• Dizziness 18%
• Malignant Neoplasm 9%
• Leukemia 9%
• Alpha Tocopherol 9%
• Adverse Event 9%
• Adenosine Triphosphate 9%
• Ubidecarenone 9%
• Side Effect 9%
• Ascorbic Acid 9%